Drug Profile
Research programme: p38 mitogen-activated protein kinase inhibitors - Eli Lilly and Company
Alternative Names: LY-479754Latest Information Update: 07 Oct 2013
Price :
$50
*
At a glance
- Originator Eli Lilly and Company
- Class Small molecules
- Mechanism of Action P38 mitogen-activated protein kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 18 Sep 2013 Discontinued - Preclinical for Cancer in USA (PO)
- 06 May 2005 Preclinical trials in Cancer in USA (PO)